Shots:

• The approval is based on MARVEL 2 study evaluating the ability of the Micra’s internal sensor- monitoring atrial contractions and enable coordinated pacing between the atrium and ventricle thus providing AV synchrony pacing therapy to patients with AV block
• The MARVEL 2 study demonstrated a greater percentage of complete heart block patients with normal sinus rhythm having >70% AV synchrony during algorithm-mediated AV synchronous pacing than VVI pacing- showed no pauses/ episodes of pacing-induced tachycardia
• Medtronic’s Micra AV is the first and only FDA-approved leadless pacemaker- has shown 63% reduction in major complication and does not require leads or a surgical "pocket" under the skin

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Medtronic